title: After Avandia, some seek split in drug approval and monitoring.
authors.forename: Elie
authors.initials: E
authors.lastname: Dolgin
mesh_terms: D034462:Dissent and Disputes; D017277:Drug Approval / Q000458:organization & administration*; D016903:Drug Monitoring / Q000379:methods / Q000592:standards*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing / Q000379:methods / Q000592:standards; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone